Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 181

The DOI matches its Crossref record.

Treatment of West Nile Virus Encephalitis with Intravenous Immunoglobulin

Open access
Shimoni, Zvi, Niven, Mark J, Pitlick, Silvio, Bulvik, Shlomo · 2001 · Emerging Infectious Diseases

Abstract

Treatment of West Nile Virus Encephalitis with Intravenous ImmunoglobulinTo the Editor: West Nile virus is endemic in Israel.The overwhelming majority of infections are mild and asymptomatic, but there have been periodic symptomatic outbreaks (1).In August 2000, an epidemic of West Nile virus broke out in Israel, with >260 confirmed cases and 20 deaths by the end of September 2000.Hitherto, the only treatment for this condition has been supportive with no proven in vivo specific therapy, although ribavirin has shown promise in in vitro studies (2).We report an apparent dramatic response to intravenous immunoglobulin in an immunosuppressed patient and suggest that this was the result of specific antibodies in the Israeli immunoglobulin used.A 70-year-old woman was admitted to the hospital because of fever and vomiting of 24 hours' duration.She had a 12-year history of chronic lymphatic leukemia (Rai stage II) but was not on treatment.A routine outpatient assessment 1 week earlier had shown no unexpected findings.On physical examination the patient appeared generally well, with temperature 39.0°C, regular pulse 100/ minute, and blood pressure 130/70.Apart from splenomegaly 2-3 cm below the costal margin, there were no abnormal physical signs, including lymphadenopathy.Chest X ray results were normal.Hb was 12 g/dL, HCt 32%, mean corpuscular volume 84, leukocyte count 280x10 9 /L (90% lymphocytes, 13% neutrophils, and 10% monocytes), platelets 280x10 9 /L, Coombs negative.Her biochemical profile was entirely within the normal range.Blood and urine cultures were negative.Immunoglobulin G (IgG) was 14.5 g/L, IgM 2.6 g/L, and IgA 2.6 g/L.Forty-eight hours after admission, dysarthria with episodes of impaired consciousness developed.After a further 24 hours, she was in deep coma (Glasgow Coma Scale, 6).Empiric treatment for presumed central nervous system infection was begun with ceftriaxone, ampicillin, acyclovir, and amphotericin B. Results of cranial computerized tomography were normal.A lumbar puncture was performed and showed clear cerebrospinal fluid (CSF) at normal pressure.CSF protein was 1.04 g/L, glucose 2.4 mmol/L, and leukocyte count 162/mm 3 (90% mononuclear cells).Gram stain was negative, as were bacterial culture, cryptococcal antigen, and results of a polymerase chain reaction test for herpes viruses.IgM antibodies against West Nile virus were positive in both serum and CSF.With the definite diagnosis of West Nile encephalitis, all antimicrobial treatment was stopped.Because of the chronic lymphatic leukemia and presumed immunosuppression, we decided to give intravenous immunoglobulin (Omr-IgG-am, Omrix Biopharmaceutical Ltd, Tel Hashomer, Israel), 0.4 g/kg, as has been recommended for this condition (3).The patient's neurologic condition remained unchanged (Glasgow coma scale, 5-6) for the next 2 days but then began to improve.Over the subsequent 5 days, her level of consciousness returned to normal.In light of this apparently dramatic response to treatment with intravenous immunloglobulin, we examined several batches of pooled immunoglobulin from different sources for antibodies to West Nile virus.Intravenous

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3201/eid0704.010432

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

Metadata

Authors
Shimoni, Z., Niven, M. J., Pitlick, S., & Bulvik, S.
Venue
Emerging Infectious Diseases
Published
2001-08
Volume
7
Issue
4
Pages
759-759
ISSN
  • 1080-6040 (ISSN-L)
  • 1080-6059
OpenAlex
W2040998612
Cited by
181
References
0
FWCI
14.76
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.